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Trust is good, control is better: 
technical considerations in 
blood microbiome analysis
We agree with Hornung et al1 that 
studying blood microbiome is a major 
technical challenge with potential arte-
facts. At least three important challenges 
must be tackled:
1. Low amount of bacterial DNA in 
blood.2
2. High amounts of PCR inhibitors.
3. Bacterial DNA contaminants from en-
vironment, reagents and consumables.
Measuring, reducing and controlling 
bacterial contaminants are key elements 
of optimisations made on the molecular 
pipeline used in our study3 as well as 
eight published studies on blood micro-
biome.2 4–7 The studies from Salter et al8 
and Laurence et al9 are useful to under-
stand the burden of bacterial contami-
nants when working with low bacterial 
abundance samples. In former publica-
tions,2 10 we have described our proce-
dure and the controls performed to 
address such contamination. One must be 
careful when using a fixed list of bacterial 
contaminants, as each experiment has its 
own contamination burden. Therefore, 
two different experiments done under 
different conditions, will not have the 
same contaminants. What is essential, 
as pointed out by Hornung et al, is to 
include and analyse negative controls in 
each experiment. Although not explicitly 
mentioned before, our study3 included the 
following negative controls:
i. Extraction negative controls (water at 
DNA extraction step).
ii. PCR negative controls (water at first 
PCR step).
We now present data from these control 
experiments. Abundance of 16S ribosomal 
RNA genes measured by quantitative PCR 
(qPCR) shows over 1000-fold differ-
ence between blood samples and extrac-
tion negative controls (figure 1A). Blood 
samples also exhibit significantly higher 
genus richness (figure 1B) and distinct 
microbiome compositions (figure 1C) 
compared with negative controls. There-
fore, the technical contamination would 
have only a marginal impact in this study. 
Though we cannot exclude that a small 
fraction of the measured bacterial DNA 
corresponds to contamination, the contam-
inants are low and relatively homogenous 
between samples and should not influence 
the statistical tests performed.
Among the nine bacterial genera listed 
by Hornung et al as potential contaminants 
based on the literature, the negative control 
sequencing data clearly show that eight of 
them were not contaminants in our study 
(figure 2A). These were either absent from 
negative controls or present in significantly 
lower relative proportions than in blood 
samples. The remaining genus, Arthrobacter, 
with similar relative abundance in samples/
controls (figure 2A), could be considered a 
contaminant. When working with composi-
tional data, it is important to note that rela-
tive abundance of contaminants in negative 
controls will be exaggerated. It should always 
be interpreted together with quantitative 
data, such as qPCR abundances (figure 1A). 
Therefore, it is disputable whether Arthro-
bacter is a real contaminant given our data, 
but still possible. Additionally, we also found 
that Escherichia/Shigella relative abundance 
could suggest that it is a contaminant, but it 
is not uncommon to find it in blood. Conse-
quently, we did not exclude Arthrobacter 
and Escherichia/Shigella, but they did not 
show clinically meaningful correlations and 
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Figure 1 (A) qPCR-based 16S rRNA gene abundances are significantly higher in buffy coat 
samples than negative controls (H2O—Ext) based on Mann-Whitney U test. Median 20 800 versus 
3 copies/µL; mean 24 160 versus 67.2 copies/µL. (B) Buffy coat samples exhibit significantly 
higher genus richness than negative controls (H2O—PCR and H2O—Ext) based on Kruskal-Wallis 
test followed by Dunn’s post hoc tests. (C) Principal coordinate analysis of the 16S rRNA gene 
sequencing data using Bray-Curtis dissimilarity measure shows clear separation of buffy coat 
samples from negatives controls (H2O—PCR and H2O—Ext). H2O—Ext: molecular grade water 
added in an empty tube, extracted and analysed (qPCR and/or sequencing) at the same time as the 
samples. H2O—PCR: molecular grade water added in an empty tube and amplified and sequenced 
at the same time as the extracted DNA of the samples. Statistical significance—*p<0.05; 
***p<0.001; ****p<0.0001. qPCR, quantitative PCR; rRNA, ribosomal RNA.
Figure 2 Comparison of bacterial genus relative abundances in buffy coat samples and negative 
controls (H2O—PCR and H2O—Ext). (A) Bacterial genera listed in the letter of Hornung et al as 
potential contaminants, and Escherichia/Shigella. (B) Two bacterial genera that were considered 
as likely contaminants and discarded from our previous letter. H2O—Ext: molecular grade water 
added in an empty tube, extracted and analysed (qPCR and/or sequencing) at the same time as the 
samples. H2O—PCR: molecular grade water added in an empty tube and amplified and sequenced 
at the same time as the extracted DNA of the samples. qPCR, quantitative PCR. 
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therefore were not discussed in our report.3 
Two other taxa (Bradyrhizobium and 
Ralstonia) were present in higher propor-
tions in negative controls compared with 
samples (figure 2B), and thus were consid-
ered as likely contaminants and not consid-
ered further.3
Finally, contamination by skin bacteria is 
indeed a major challenge when using small 
volume of blood (20 µL) taken by skin punc-
ture. However, in this study, 40 mL of blood 
was withdrawn. Moreover, portal, hepatic 
and atrial blood were collected using cath-
eters not in contact with skin. Therefore, 
contamination from the skin is negligible in 
our study.
Overall, we second the concerns raised 
by Hornung et al, and through this letter 
highlight the important controls required 
in blood microbiome research.
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